atrial fibrillation

90 all articles · 20 / page

Ask MedXY AI

Latest news

Tag

All articles

Vernakalant Beats Procainamide for Rapid ED Cardioversion of Recent-Onset Atrial Fibrillation: Results from RAFF4

The RAFF4 randomized trial found intravenous vernakalant superior to procainamide for rapid cardioversion of acute atrial fibrillation in the emergency department — higher conversion within 30 minutes, faster time to sinus rhythm, and fewer

Section: CardiologyNov 22, 2025

Daily Caffeinated Coffee After Cardioversion Cuts Atrial Fibrillation Recurrence: Results from the DECAF Randomized Trial

The DECAF randomized trial found that encouraging caffeinated coffee consumption (≈1 cup/day) after successful cardioversion reduced clinically detected AF/flutter recurrence over 6 months versus caffeine abstinence (47% vs 64%; HR 0.61). R

atrial fibrillation

Latest news

Vernakalant Beats Procainamide for Rapid ED Cardioversion of Recent-Onset Atrial Fibrillation: Results from RAFF4

Daily Caffeinated Coffee After Cardioversion Cuts Atrial Fibrillation Recurrence: Results from the DECAF Randomized Trial

NOAC Monotherapy After Drug‑Eluting Stent: Safer and at Least as Effective as NOAC Plus Clopidogrel in AF Patients ≥1 Year After PCI

Does Anticoagulation After Successful AF Ablation Matter? The OCEAN Trial Shows No Clear Advantage of Rivaroxaban over Aspirin

Mitochondrial Calcium Deficit Links Structural Remodeling to Atrial Fibrillation — and an Old Cholesterol Drug, Ezetimibe, Shows Unexpected Anti‑AF Potential

Active Monitoring for Atrial Fibrillation (AMALFI): Advancing Long-Term Remote Screening to Reduce Stroke Risk

Remote ECG Patch Screening for Asymptomatic Atrial Fibrillation: Insights from the AMALFI Trial

Reevaluating New-Onset Atrial Fibrillation After CABG: Insights from Long-Term Continuous Monitoring

Age-Stratified Outcomes of Rivaroxaban Monotherapy in Atrial Fibrillation with Stable Coronary Artery Disease: Insights from the AFIRE Trial

Abelacimab Shows Consistent Bleeding Safety Across Kidney Function in Atrial Fibrillation: Insights from the AZALEA-TIMI 71 Trial

Rivaroxaban vs Warfarin in Postcardiac Surgery Atrial Fibrillation: Insights from the NEW-AF Trial

Catheter Ablation vs Drug Therapy for Atrial Fibrillation: Insights from the CABANA Trial by Nonmodifiable Risk Profiles

Impact of Diabetes and Obesity on Early Rhythm Control Outcomes in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial

Serum Carboxymethyl-Lysine and Its Prospective Associations with Heart Failure and Atrial Fibrillation in Older Adults: Insights from the Cardiovascular Health Study

Biomarker-Guided ABC-AF Risk Scores: Evaluating Their Role in Personalized Therapy for Atrial Fibrillation

Biomarker-Guided ABC-AF Risk Scores in Atrial Fibrillation: Insights from a Large Multicenter Randomized Trial

Low-Dose Digoxin Enhances Cardiac Function in Heart Failure with Preserved EF and Atrial Fibrillation: Insights from the RATE-AF Trial

Reevaluating Long-Term Anticoagulation After Atrial Fibrillation Ablation: Insights from the ALONE-AF Randomized Trial

Epicardial Adipose Tissue as a Predictor of New-Onset Atrial Fibrillation: Insights from a Danish Population Cohort